Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355570 | 0.98 | OPRM1 (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL9131464 | 0.96 | CTSL (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL61112 | 0.96 | CTSL (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL3660170 | 0.94 | OPRM1 (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| Phenol SCHEMBL28176960 | 0.90 | OPRM1 (0.50) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL6469380 | 0.89 | OPRM1 (0.59) | OPRM1OPRL1DPP4CTSLCTSB | |
| Phenol SCHEMBL28176920 | 0.89 | CTSL (0.50) | OPRM1OPRL1DPP4CTSLCTSB | |
| Methyl Alcohol SCHEMBL10438266 | 0.88 | OPRM1 (0.55) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL24752799 | 0.87 | DPP4 (0.51) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL29064882 | 0.87 | ALDH1A1 (0.50) | OPRM1OPRL1DPP4CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300923-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7271157-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1789431-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1768991-A1 | PROCESS FOR THE PREPARATION OF A1-ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060052330-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2006026651-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017052-A1 | PROCESS FOR THE PREPARATION OF A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060009417-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-01-12 | — | — | US | disclosed |
| US-6214608-B1 | ACYLATING PRIMARY AND SECONDARY OXYGEN OR NITROGEN SUBSTITUTED AMINES BY REACTING AMINE WITH ESTER IN PRESENCE OF LIPASE | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052330-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | OPRM1 224/4885OPRL1 219/4885DPP4 2364/4885 |
| US-20060009417-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | OPRM1 197/4885OPRL1 148/4885DPP4 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.